Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

被引：2
|
作者：
Opdam, F. [1 ]
Heymach, J. [2 ]
Ruiter, G. [3 ]
Barve, M. [4 ]
Tu, H. [5 ]
Wu, Y-L. [5 ]
Schroeter, L. [6 ]
Sadrolhefazi, B. [7 ]
Serra, J. [8 ]
Yoh, K. [9 ]
Yamamoto, N. [10 ]
机构：
[1] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[2] Univ Texas Houston, Div Canc Med, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Houston, TX USA
[3] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Thorac Oncol & Phase 1 Studies, NKI AVL, Amsterdam, Netherlands
[4] Mary Crowley Canc Res Ctr, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Oncol, Ridgefield, CT USA
[8] Boehringer Ingelheim SA, CD&O, Sant Cugat Del Valles, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1375P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations:A HER2-CS STUDY subset analysis.
    Kayatani, Hiroe
    Aoe, Keisuke
    Ohashi, Kadoaki
    Yoshioka, Hiroshige
    Bessho, Akihiro
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Kozuki, Toshiyuki
    Fujimoto, Nobukazu
    Ueda, Yutaka
    Bandoh, Syuuji
    Murakami, Isao
    Ichikawa, Hirohisa
    Kubota, Tetsuya
    Sugimoto, Keisuke
    Takigawa, Nagio
    Sumikawa, Takashi
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] POPULATION PHARM ACOKINETICS OF FS-1502, AN HER2 ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH HER2 EXPRESSED ADVANCED MALIGNANT SOLID TUMORS.
    Sun, Y.
    Li, C.
    Diao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S96 - S96
  • [43] A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
    Haense, N.
    Atmaca, A.
    Pauligk, C.
    Steinmetz, K.
    Marme, F.
    Haag, G. M.
    Rieger, M.
    Ottmann, O. G.
    Ruf, P.
    Lindhofer, H.
    Al-Batran, S. -E.
    BMC CANCER, 2016, 16
  • [44] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Feng Guo
    Stephen P. Letrent
    Pamela N. Munster
    Carolyn D. Britten
    Karen Gelmon
    Anthony W. Tolcher
    Amarnath Sharma
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 97 - 109
  • [45] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Guo, Feng
    Letrent, Stephen P.
    Munster, Pamela N.
    Britten, Carolyn D.
    Gelmon, Karen
    Tolcher, Anthony W.
    Sharma, Amarnath
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 97 - 109
  • [46] Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors
    Miao, Zhenwei
    Lin, Fengjuan
    Rao, Xi
    Huang, Yong
    Wang, Feng
    Lu, Yao
    Huang, Xiuying
    Huang, Yunsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
    Li, Bob T.
    Li, Tianhong
    Johnson, Melissa Lynne
    Waqar, Saiama Naheed
    Zhu, Viola Weijia
    Ou, Sai-Hong Ignatius
    Lin, Jessica Jiyeong
    Wang, Ding
    Shapiro, Geoffrey
    Wang, Judy Sing-Zan
    Liu, Dazhi
    Ye, Yuqing
    Kosar, Hana
    Hee, Angela
    Berk, Greg
    Zhang, Sean
    Wang, Junsheng
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A pharmacodynamic pilot study of DS8201a in patients with HER2 expressing advanced solid tumors
    Shin, Sarah J.
    -Coyne, Geraldine O'Sullivan
    Lee, Elizabeth K.
    Mittra, Arjun
    Sternberg, Cora N.
    Ong, Mary Jane
    Wilsker, Deborah
    Ferry-Galow, Katherine
    Foster, Jared
    Juwara, Lamin
    Takebe, Naoko
    Pickett, Cheryl A.
    Parchment, Ralph
    Doroshow, James
    Chen, Alice
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [49] Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Moulder, Stacy L.
    Borges, Virginia F.
    Baetz, Tara
    Mcspadden, Tessa
    Fernetich, Gina
    Murthy, Rashmi K.
    Chavira, Renae
    Guthrie, Kari
    Barrett, Emma
    Chia, Stephen K.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3529 - 3536
  • [50] Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations
    Wu, Y. -L.
    Opdam, F.
    Yamamoto, N.
    Yoshida, T.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S348 - S348
12345